Pharmaceutical cleanrooms have strict environmental requirements that conflict with fire safety provisions. Engineering the balance.. Pharmaceutical Cleanroom Fire Safety in the UK UK pharmaceutical, advanced therapy medicinal product (ATMP), vaccine fill finish and biotech cleanroom facilities — from AstraZeneca Macclesfield to GSK Stevenage and the cell and gene therapy clusters at Stevenage Bioscience Catalyst and Cambridge — operate under MHRA GMP, EU Annex 1:2022 and ISO 14644 environmental controls that directly conflict with conventional fire safety provisions. The Regulatory Reform (Fire Safety) Order 2005, DSEAR 2002, COMAH 2015 (where flammable inventories trigger thresholds), and the Building Safety Act 2022 all apply concurrently. Designing safely requires integrated fire engineering with process, HVAC, qualification and quality teams from concept stage. Cleanroom Specific Design Conflicts HEPA filtered laminar flow disrupts conventional ionisation and optical smoke detection performance. Positive cascade pressure (Grade A→D) opposes natural smoke extract and fire door operation. Sprinkler discharge or wet pre action contaminates batches and forces validated clean down lasting weeks. Single pass airflow and airlocks lengthen escape distances; gowning rooms double as means of escape bottlenecks. Process solvents (ethanol, IPA, acetone) trigger DSEAR Zone 1/2 classification within otherwise low risk envelopes. Specialist Engineering Solutions VESDA E aspirating smoke detection with sampling pipes located upstream of HEPA filters and in return air paths. Inert gas (IG 541, IG 55) or fluoroketone (Novec 1230) clean agent suppression sized to BS EN 15004 with door fan integrity testing. Air handling unit fire mode programming: staged isolation preserving cascade pressure to maintain containment of cytotoxic or biological products. Two stage alarm with quality team confirmation prior to suppression release to avoid unnecessary batch loss. Fire rated airlock construction (60 minutes) with panic release mag locks compliant with BS 7273 4. MHRA GMP and Annex 1:2022 Considerations All fire safety equipment in classified areas must be qualified (IQ/OQ/PQ) and listed in the validation master plan. Suppression agent residues must be evaluated for product contamination risk and documented in the Contamination Control Strategy. Annual fire system functional tests must be coordinated with cleanroom requalification windows. Documentation must withstand MHRA, FDA and EMA inspection scrutiny. Magnus Opifex Seven Pharmaceutical Service We provide integrated fire engineering for UK pharmaceutical, ATMP, vaccine and biotech facilities, combining BS 9999 risk based design, BS EN 15004 clean agent specification, DSEAR risk assessment and GMP validated documentation packs. For pharmaceutical fire safety, contact Magnus Opifex. Magnus Opifex SEVEN LTD — UK's Leading Fire Safety & Fire Engineering Consultancy 🌐 magnus opifex.co.uk 📞 +44 7486 691724 ✉️ office@magnus opifex.co.uk Founders: Nicoleta Vasile, Baroness of Brattleby — CEO, Lawyer and Barrister, Legal & Administrative Director Alina — Technical Director & Expert Fire Engineer (BEng) Head Office: Ealing Cross, 85 Uxbridge Road, London W5 5BW Magnus Opifex SEVEN LTD delivers engineering led fire engineering, fire risk assessments, CFD modelling, and building safety consultancy across the United Kingdom and internationally. With over 20 years of combined experience and a UK portfolio spanning healthcare, residential and infrastructure, we bring truly engineered solutions with a personal touch. © 2026 Magnus Opifex SEVEN LTD. All rights reserved.